GLP-1 Costs Test Retirement Investing, Survey Finds

Picture a monthly budget with two recurring lines that both feel non-negotiable. One is a prescription that people say is helping them feel healthier. The other is the automatic contribution that is supposed to fund a future retirement. According to a new survey from Nationwide, a growing number of Americans on GLP-1 medications fear those two lines may collide.

The findings, distributed through PR Newswire on October 7, 2026, put a financial-planning lens on one of the most discussed drug categories of the moment. For anyone who thinks about long-term investing, the data raises a simple question: what happens to saving rates when health spending rises?

Key takeaways

• Nationwide reports that half of current GLP-1 users worry they may have to choose between paying for their medication and saving for retirement.
• The same survey found nearly nine in 10 users are optimistic about their long-term health.
• Nationwide says medication costs are creating new financial and retirement planning challenges.
• The results come from a company-sponsored survey, so readers should weigh them accordingly.

What the survey says

The headline finding is a tension. Users are hopeful about their health, with nearly nine in 10 expressing optimism about the long term. Yet half say they may eventually have to trade off between keeping up with the medication and putting money toward retirement.

Those two results do not contradict each other. A person can believe a treatment is working and still worry about how long they can afford it. The survey, as described by Nationwide, treats cost as the pressure point, not effectiveness or willingness to stay on therapy.

The summary available to us does not give the sample size, the survey dates, the margin of error, or how “current GLP-1 users” were defined. Those details matter when judging how far the numbers generalize.

Why this matters for retirement investing

Retirement outcomes depend on steady contributions over decades. Any new recurring expense that competes with those contributions can matter, particularly if it is open-ended. A medication taken indefinitely behaves less like a one-off bill and more like a permanent change to the household cost base.

A recurring health cost that people see as essential does not just trim a budget. It can quietly reorder financial priorities, and retirement contributions are often the easiest line to defer.

That dynamic is the real story behind the survey. Retirement saving is usually the flexible item in a household budget, because nothing is due today if it is skipped. Respondents describing a possible choice between medication and savings are, in effect, describing that flexibility being tested.

Who is affected

The most direct group is people who currently take GLP-1 medications and are also saving for retirement. Beyond them, the findings are relevant to employers who design benefits, to financial advisors who build plans around spending assumptions, and to fintech companies that offer budgeting, savings and retirement tools.

For product teams, the signal is that health-related spending may deserve a more explicit place in planning software. Many retirement calculators model generic inflation and healthcare in retirement. They are less likely to account for a costly medication taken during peak earning years that reduces what can be saved.

What to watch next

Several questions follow from this release.

• Methodology. Fuller details on the survey’s design would show how representative the half-of-users figure is.
• Behavior versus worry. The survey describes concern about a possible choice. Whether people actually cut contributions is a separate question that future research or plan-level data could answer.
• Coverage and pricing. Out-of-pocket exposure depends on insurance and pricing, and changes there would shift how acute this trade-off feels. The source material does not address those factors, so this remains an open variable.
• Financial-tool response. Watch whether retirement platforms and advisors start building health-cost scenarios into their standard planning flows.

The bottom line

This is a single company’s survey, and it should be read as a data point rather than a verdict. Still, it captures a plain financial reality: a treatment that many users feel good about can create a budgeting dilemma, and retirement savings may be where the squeeze lands. For fintech news watchers, the more interesting question is whether planning tools and employers adapt to that reality before it shows up in savings data.

This article is for information only and is not investment or financial advice.